Media Advisory - Oncolytics Biotech Inc. to Present at BioPartner...(toupdate these forward-looking statement...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
Date:10/9/2008
to update these forward-looking statements, except as required by applicable laws.
'/>"/>
| SOURCE Oncolytics Biotech Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference
2. Cell Therapeutics Provides Details on Investor & Media Day to be Held in Milan, Italy on Friday, October 3, 2008
3. Huifeng Bio-pharmaceutical Technology Inc. Announces Strategic Alliance with Premier Media Service Inc.
4. U.S. News Media Group Releases 19th Edition of Americas Best Hospitals
5. VIDEO from Medialink and Med-El: New Technology is Music to Peoples Ears
6. BioLife Solutions Announces FDA Master File Acceptance for CryoStor(TM) Pre-formulated Cryopreservation Media
7. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System
8. Media Advisory - Oncolytics Biotech Inc. to Present at BioSquare 2008
9. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
10. Intellisphere Announces Acquisition of Multiple Titles from Ascend Medias Healthcare Division
11. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
Post Your Comments:
Breaking Biology Technology:Myriant Technologies LLC Selected for $50 Million Award for Succinic Acid Biorefinery Project 2Vivakor Announces Additions to Board of Directors and Scientific Advisory Board 2Vivakor Announces Additions to Board of Directors and Scientific Advisory Board 3Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4
[0] Myriant Technologies LLC Selected for $50 Million Award for Succinic Acid Biorefinery Project[0] Vivakor Announces Additions to Board of Directors and Scientific Advisory Board[0] Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer[0] Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A
Other Biology Technology:Xenon Announces Appointment of VP, Discovery Research 2'T-ray' breakthrough signals next generation of security sensors 2Linc Facility Services Acquires Morse Medical 2
Breaking Biology News(10 mins):ISWA calls attention to important contribution of waste sector to reduce substantial CO2 emissions 2Spices halt growth of breast stem cells, U-M study finds 2New York autopsies show 2009 H1N1 influenza virus damages entire airway 2New York autopsies show 2009 H1N1 influenza virus damages entire airway 3Facial Structure May Hold Clues to Aggression 61341 1Hip Fracture Odds Rise With Womens Age 61338 1Employer Medicare Provisions of House Health Care Reform Detailed in New CCH Briefing 61335 1Employer Medicare Provisions of House Health Care Reform Detailed in New CCH Briefing 61335 2Employer Medicare Provisions of House Health Care Reform Detailed in New CCH Briefing 61335 3Employer Medicare Provisions of House Health Care Reform Detailed in New CCH Briefing 61335 4Employer Medicare Provisions of House Health Care Reform Detailed in New CCH Briefing 61335 5
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |